Metformin and inflammation: Its potential beyond glucose-lowering effect

Yoshifumi Saisho

研究成果: Article査読

280 被引用数 (Scopus)

抄録

Metformin is an oral hypoglycemic agent which is most widely used as first-line therapy for type 2 diabetes. Metformin improves hyperglycemia by suppressing hepatic glucose production and increasing glucose uptake in muscle. Metformin also has been shown to reduce cardiovascular events in randomized controlled trials; however, the underlying mechanism remains to be established. Recent preclinical and clinical studies have suggested that metformin not only improves chronic inflammation through the improvement of metabolic parameters such as hyperglycemia, insulin resistance and atherogenic dyslipidemia, but also has a direct anti-inflammatory action. Studies have suggested that metformin suppresses inflammatory response by inhibition of nuclear factor κB (NFκB) via AMP-activated protein kinase (AMPK)-dependent and independent pathways. This review summarizes the basic and clinical evidence of the anti-inflammatory action of metformin and discusses its clinical implication.

本文言語English
ページ(範囲)196-205
ページ数10
ジャーナルEndocrine, Metabolic and Immune Disorders - Drug Targets
15
3
出版ステータスPublished - 2015 9月 1

ASJC Scopus subject areas

  • 内分泌学、糖尿病および代謝内科学
  • 免疫アレルギー学

フィンガープリント

「Metformin and inflammation: Its potential beyond glucose-lowering effect」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル